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ORIGINAL ARTICLE
Study of Flare Assessment in Systemic Lupus
Erythematosus Based on Paper Patients
D. ISENBERG,1 J. STURGESS,2 E. ALLEN,2 C. ARANOW,3 A. ASKANASE,4 B. SANG-CHEOL,5
S. BERNATSKY,6 I. BRUCE,7 J. BUYON,8 R. CERVERA,9 A. CLARKE,10 MARY ANNE DOOLEY,11
P. FORTIN,12 E. GINZLER,13 D. GLADMAN,14 J. HANLY,15 M. INANC,16 S. JACOBSEN,17 D. KAMEN,18
M. KHAMASHTA,19 S. LIM,20 S. MANZI,21 O. NIVED,22 C. PESCHKEN,23 M. PETRI,24 K. KALUNIAN,25
A. RAHMAN,1 R. RAMSEY-GOLDMAN,26 J. ROMERO-DIAZ,27 G. RUIZ-IRASTORZA,28
J. SANCHEZ-GUERRERO,29 K. STEINSSON,30 G. STURFELT,22 M. UROWITZ,14
R. VAN VOLLENHOVEN,31 D. J. WALLACE,32 A. ZOMA,33 J. MERRILL,34 AND C. GORDON35
Objective. To determine the level of agreement of disease flare severity (distinguishing severe,moderate, andmild flare and
persistent disease activity) in a large paper-patient exercise involving 988 individual cases of systemic lupus erythematosus.
Methods. A total of 988 individual lupus case histories were assessed by 3 individual physicians. Complete agreement
about the degree of flare (or persistent disease activity) was obtained in 451 cases (46%), and these provided the reference
standard for the second part of the study. This component used 3 flare activity instruments (the British Isles Lupus Assess-
ment Group [BILAG] 2004, Safety of Estrogens in Lupus Erythematosus National Assessment [SELENA] flare index [SFI]
and the revised SELENA flare index [rSFI]). The 451 patient case histories were distributed to 18 pairs of physicians, care-
fully randomized in amanner designed to ensure a fair casemix and equal distribution of flare according to severity.
Results. The 3-physician assessment of flare matched the level of flare using the 3 indices, with 67% for BILAG 2004, 72%
for SFI, and 70% for rSFI. The corresponding weighted kappa coefficients for each instrument were 0.82, 0.59, and 0.74,
respectively.We undertook a detailed analysis of the discrepant cases and several factors emerged, including a tendency to
score moderate flares as severe and persistent activity as flare, especially when the SFI and rSFI instruments were used.
Overscoring was also driven by scoring treatment change as flare, even if there were no new orworsening clinical features.
Conclusion. Given the complexity of assessing lupus flare, we were encouraged by the overall results reported. How-
ever, the problem of capturing lupus flare accurately is not completely solved.
INTRODUCTION
In the past 30 years, methods of assessing disease activity in
patients with lupus have improved considerably. Both global
score systems, such as the Systemic Lupus Erythematosus
DiseaseActivity Index (SLEDAI), the Systemic LupusActivity
Measures, and the EuropeanCommunity LupusActivityMea-
sure, and more specific instruments such as the British Isles
Lupus Assessment Group (BILAG) system, which focuses on
individual organs or systems, have emerged as viable and
effective activity assessment instruments. SLEDAI and BILAG
have been revised to SLEDAI-2K (1) and theBILAG2004 index
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(2), with large-scale studies undertaken to demonstrate their
validity, reliability, and sensitivity to change (3).
Although both the SLEDAI and BILAG activity assess-
ments are widely used in large-scale international trials of
new biologic drugs (4–6), there are few data assessing their
usefulness in determining clinical flares in patients with
lupus (7). The Lupus Foundation of America held 2 investi-
gator meetings in 2007 and 2008 that sought to agree on the
definition of flare in lupus patients (8). They concluded
that flare is “a measurable increase in disease activity in 1
or more organ systems involving new or worse clinical
signs and symptoms and/or laboratory measurements. It
must be considered clinically significant by the assessor
and usually there will be at least consideration of initiation
or increase in treatment.”
A particular challenge in patients with lupus has been
distinguishing mild, moderate, and severe flares and distin-
guishing them from ongoing, persistent disease. This prob-
lem is in part related to difficulties in agreeing what
constitutes such flares in different organs and systems,
but also because when a patient is flaring there may be a
difference in the degree of flare in different organs or
systems.
A live patient study of 16 flaring patients with lupus (9)
took place in London in May 2009. In that study, 3 assess-
ment instruments were used to assess flare. One was based
on the BILAG 2004 index, a second was the classic Safety
of Estrogens in Lupus Erythematosus National Assessment
(SELENA) flare index (SFI), and the third was the revised
SELENA flare index (rSFI), an organ-based system that is
based on, but not directly linked to, the SLEDAI.
In that live patient study (9), a panel of rheumatologists,
one of whom was the patient’s own clinician, determined
the severity of flare in each patient, and then different indi-
vidual rheumatologists assessed each patient for flare with
all 3 instruments. Intraclass correlation coefficients (with
95% confidence interval [95% CI]) were calculated to indi-
cate a measure of internal reliability. The results were 0.54
(95% CI 0.32–0.78) for the BILAG 2004 flare assessment
compared with 0.21 (95% CI 0.08–0.48) for the revised
SELENA flare index and 0.18 (95% CI 0.06–0.45) for the
physicians global assessment of flare. Severe flare was asso-
ciated with good agreement between the 3 instruments, but
the mild-to-moderate flares were less consistent. Although
assessing real patients offers the tangible advantage of test-
ing potential flare instruments in a more realistic way, obvi-
ously the numbers of patients (and their clinical problems)
that can be studied at any given time is restricted. To
expand our experience of flare assessment in lupus, we
have now undertaken a major paper-patient–based exercise,
which has allowed us to review a much broader array of
lupus symptomatology and to use a larger number of asses-
sors to determine flare status, using individual instruments
on paper case reports based on real cases. The objective of
this study was to determine the level of agreement of flare
severity (severe/moderate/mild/none, i.e., persistent dis-
ease activity) identified in paper-patient cases using 3 flare
instruments and physician-defined flares determined by a
panel of 3 physicians.
MATERIALS AND METHODS
Generation of clinical case scenarios. Participating
physicians were given a standardized report form to com-
plete, which included 4 sections: previous lupus assessment
and treatment, details of assessment at the visit being eval-
uated for flare, results of relevant investigations (blood,
urine, imaging, biopsies, etc.) influencing this assessment,
and treatment changes at this visit. Thirty physicians
submitted a total of 988 anonymous individual paper case
reports, based on the medical records of their patients. Each
patient met the revised classification criteria of the Ameri-
can College of Rheumatology (10) and/or the 2012 Systemic
Lupus International Collaborating Clinics criteria (11). The
Charleston; 19M. Khamashta, FRCP: King’s College London,
London, UK; 20S. Lim, MD: Emory University, Atlanta,
Georgia; 21S. Manzi, MD: Allegheny Health Network, Pitts-
burgh, Pennsylvania; 22O. Nived, MD, G. Sturfelt, MD: Lund
University, Lund, Sweden; 23C. Peschken, MD: University of
Manitoba, Winnipeg, Manitoba, Canada; 24M. Petri, MD: Johns
Hopkins University, Baltimore, Maryland; 25K. Kalunian, MD:
University of California at San Diego; 26R. Ramsey-Goldman,
MD: Northwestern University, Feinberg School of Medicine,
Chicago, Illinois; 27J. Romero-Diaz, MD: Instituto Nacional de
Ciencias Medicas y Nutricion, Mexico City, Mexico; 28G. Ruiz-
Irastorza, MD: Hospital Universitario Cruces and University
of theBasqueCountry, Barakaldo, Spain; 29J. Sanchez-Guerrero,
MD: Mount Sinai Hospital and University Health Network and
University of Toronto, Toronto, Ontario, Canada; 30K. Steinsson,
MD: Landspitali University Hospital, Reykjavik, Iceland;
31R. van Vollenhoven, MD: Karolinska University Hospital,
Solna, Sweden; 32D. J. Wallace, MD: University of California at
LosAngeles; 33A. Zoma, PhD: HairmyresHospital, East Kilbride,
Scotland, UK; 34J. Merrill, MD: Oklahoma Medical Research
Foundation, Oklahoma City; 35C. Gordon, PhD: College of
Medical and Dental Sciences, University of Birmingham,
Birmingham,UK.
Address correspondence to D. Isenberg, MD, Centre for
Rheumatology, University College London, London, UK.
E-mail: d.isenberg@ucl.ac.uk.
Submitted for publication August 3, 2016; accepted in
revised form April 4, 2017.
Significance & Innovations
• This study addresses the ongoing dilemma of how
best to capture flare in patients with systemic
lupus erythematosus. In our previous attempt to
measure flare using 16 live patients, we could only
assess a modest number of lupus manifestations.
• In the current studywe have used nearly 1,000 paper-
based case histories to determine the capacity of 3
flare activity instruments (British Isles Lupus Assess-
ment Group 2004 index, Safety of Estrogens in Lupus
Erythematosus National Assessment [SELENA] flare
index, and the revised SELENA flare index to capture
flare.
• We show that all 3 instruments are able to do
this in many cases, but there is an ongoing need
to do even better.
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submitting physician was also asked to provide their assess-
ment of the flare category for the paper-patient case (severe,
moderate, or mild flare or persistent/ongoing disease) and to
submit roughly equal numbers of each category. The actual
distribution of paper-patient cases received was 25% severe,
28% moderate, 22% mild, and 25% persistent disease
activity without flare.
Each patient case report was then assessed for flare cate-
gory by 2 additional reviewing physicians who did not
know the patient. The cases were allocated at random, and
randomization was designed to ensure an equal distribution
of submitted category types and to ensure that no physician
reviewed their own submitted cases or the same case twice.
The flare category assigned by each of the 3 physicians (1
submitting and 2 reviewing) was then compared.
All 3 physicians agreed on the flare category in 451 cases
(46%). We refer to this flare assessment agreement as 3-phy-
sician consensus (TPC), and these are the cases that were
carried forward to be assessed by the flare instruments in
the study. The TPC result for each case formed the refer-
ence standard for our later analyses. Flare category distribu-
tion in these cases was 32% severe, 21% moderate, 24%
mild, and 23% persistent disease without flare.
TPC was not achieved in 535 cases (54%). In 376 cases
(38%) there was partial agreement, i.e., any 2 physicians
agreed with each other (but not with the third physician),
in 41 cases (4%) there was no agreement between any
physician, i.e., all 3 physicians recorded different levels of
flare or persistent activity for these cases. One or 2 of the
reviewing physicians rejected 118 cases (12%) as unable to
code on the information provided. Two of the authors (DI
and CG) reviewed these cases to assess whether there were
any particular reasons why it was difficult to achieve TPC.
The 451 TPC patient case histories were carefully reviewed
by one author (DI) and assigned into 1 of 8 clinical groups:
musculoskeletal and/or skin disease only, joint and/or skin
and renal disease, mainly serositis, mainly renal, mainly gas-
trointestinal, mainly central nervous system, joints and/or
skin plus serositis, and other, which included predominantly
hematologic and/or constitutional or other combinations.
Two cases were excluded from further assessment, as 1 was
found to be a duplicate, and in the other the case report form
had been completed incorrectly.
Assessment of TPC paper case reports using standard
instruments. The 451 TPC patient case histories were dis-
tributed to 18 pairs of physicians. The cases were random-
ized in a manner designed to ensure each pair received a fair
case mix, based on the clinical groups set out above and an
equal distribution of flare by category type.
The 18 pairs of rheumatologists were each asked to agree
on the level of flare in 20–26 individual paper cases. Each
pair was assigned to use 1 of the 3 flare assessment instru-
ments: the BILAG 2004 index (12) (6 pairs), the SFI (13) (6
pairs), and the rSFI (9) (6 pairs). Full details of the flare
instruments are shown in Supplementary Appendices A–E
(available on the Arthritis Care & Research web site at
http://onlinelibrary.wiley.com/doi/10.1002/acr.23252/abstract).
Analyses were done both including and excluding flare
defined only by treatment change.
The pairs of rheumatologists were asked to undertake
the assessments of flare using the instrument assigned to
them separately and then to confer to achieve full agree-
ment on the score and level of flare using that instrument
or to record persistent activity without flare.
Statistical methods used. For each flare instrument, the
level of flare agreed by the assessing pair of physicians was
compared to the TPC flare assessment (the reference
standard) for each case. The level of agreement between the
flare instrument used and the TPC flare assessment was
determined in 2 ways, first by simply calculating the per-
centage of cases where there was complete agreement, and
second by calculating a weighted kappa coefficient with
quadratic weights (equivalent to an intraclass correlation
coefficient). The weighted kappa coefficient gives weights to
the frequencies in each cell of the table according to their
distance from the diagonal, thus allowing different levels of
agreement to contribute.
RESULTS
Of the 451 cases, 7 were rejected by the pairs of physicians
for providing too little information to score using the
assigned flare instrument (6 cases for the BILAG 2004 index
and 1 for the SFI flare instrument). Each type of flare that
was assessed by the BILAG 2004 is shown in Table 1, by
the SFI in Table 2, and by the rSFI in Table 3, and com-
pared with the TPC level of flare. Different clinical cases
were assessed by each instrument, so the indices cannot be
directly compared with each other.
For all 3 flare instruments, agreement on the level of flare
as assessed by each instrument and by the TPC assessment
occurred in a similar proportion of cases. The level of flare
Table 1. Number of cases by BILAG 2004 flare assessment and percent agreement with TPC
flare assessment*
Assessment No Mild Moderate Severe Total
No flare 27 (75)† 11 (31) 2 (7) 0 40 (27)
Mild flare 4 (11) 23 (64)† 6 (21) 2 (4) 35 (24)
Moderate flare 1 (3) 0 9 (31)† 4 (8) 14 (9)
Severe flare 2 (6) 0 11 (38) 41 (85)† 54 (36)
Insufficient information 2 (6) 2 (6) 1 (3) 1 (2) 6 (4)
Total 36 36 29 48 149
* Values are the number (%). BILAG = British Isles Lupus Assessment Group; TPC = 3-physician consensus.
† Statistically significant.
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matched the TPC assessment of flare in the individual cases
in a similar proportion of times using the original versions
of these instruments: 67% for BILAG 2004 index, 72% for
SFI, and 70% for rSFI. The corresponding weighted kappa
coefficients for each instrument were BILAG 2004 index j =
0.82, SFI j = 0.59, and rSFI j = 0.74.
An analysis of the discrepant cases where there was a dif-
ference in the assessment of flare between the TPC and the
flare instrument was undertaken. There was a consistent
pattern across all 3 instruments of a tendency to score mod-
erate flares as severe, as well as scoring some of the no
flare/persistent activity cases as flare when the SFI and rSFI
instruments were used. Close examination of the data in
Tables 2 and 3 suggested that this overscoring was driven
by scoring a treatment change as flare, even if there were no
new or worsening clinical features. Tables 2 and 3 also
show the adjusted results. Only 1 of the 17 cases assessed
by the SFI flare instrument as a flare, but as no flare by TPC,
had increased lupus activity without treatment change, and
in 2 cases the treatment change led to a higher level of flare
than the clinical features alone would have scored. With
the rSFI instrument, only 1 of 5 cases recorded as severe
SELENA flare, but no flare by TPC, had clinical features of
flare; the others were due to treatment change alone. In 1
case there was mild flare by TPC but severe SELENA flare
due to treatment change. Excluding flare defined primarily
by treatment change when assessing flares (Tables 2 and 3)
using the SFI and rSFI led to an increase in the proportion
of cases with agreement between the TPC and the instru-
ments to 79% and 78%, respectively, and improved the
weighted kappa scores to j = 0.82 and j = 0.73, respec-
tively.
For the cases assessed by the BILAG 2004 index in
Table 1, there were 2 cases with severe BILAG flare that
Table 2. SFI flare assessment and percent agreement with TPC flare assessment, and
assessment excluding flare defined by treatment change*
Assessment No Mild/moderate (combined) Severe Total
SELENA
No flare 17 (49)† 5 (7) 0 22 (15)
Mild/moderate flare 8 (23) 49 (67)† 0 57 (38)
Severe flare 9 (26) 19 (26) 44 (100)† 72 (47)
Insufficient information 1 (3) 0 0 1
Total 35 73 44 152
SELENA without flare defined by
treatment change
No flare 22 (63)† 10 (14) 0 32 (21)
Mild/moderate flare 8 (23) 53 (73)† 0 61 (40)
Severe flare 4 (11) 10 (14) 44 (100)† 58 (38)
Insufficient information 1 (3) 0 0 1
Total 35 73 44 152
* Values are the number (%). SFI = Safety of Estrogens in Lupus Erythematosus National Assessment/Systemic
Lupus Erythematosus Disease Activity Index; TPC = 3-physician consensus.
† Statistically significant.
Table 3. Revised SELENA flare assessment and percent agreement with TPC flare assessment, and
assessment excluding flare defined by treatment change*
Assessment No Mild Moderate Severe Total
Revised SELENA flare index
No flare 18 (58)† 0 0 0 18 (12)
Mild flare 4 (13) 16 (44)† 0 0 20 (13)
Moderate flare 4 (13) 19 (53) 19 (63)† 1 (2) 43 (29)
Severe flare 5 (16) 1 (3) 11 (37) 52 (98)† 69 (46)
Insufficient information 0 0 0 0 0
Total 31 36 30 53 150
Revised SELENA flare index without flare
defined by treatment change
No flare 23 (74)† 0 0 2 (4) 25 (17)
Mild flare 4 (13) 25 (69)† 5 (16.7) 1 (2) 35 (23)
Moderate flare 3 (10) 11 (31) 23 (77)† 3 (6) 40 (27)
Severe flare 1 (3) 0 (0) 2 (7) 47 (89)† 50 (33)
Insufficient information 0 0 0 0 0
Total 31 36 30 53 150
* Values are the number (%). SELENA = Safety of Estrogens in Lupus Erythematosus National Assessment; TPC = 3-phy-
sician consensus.
† Statistically significant.
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were appropriately scored, and it was not clear why the
TPC assessment was of no flare. For the 2 cases with se-
vere flare by TPC assessed as mild by the BILAG asses-
sors, review suggested that they had not been scored
correctly and that the criteria for severe flare (BILAG A
scores) were present in both cases. There were also 2 of
4 cases recorded by TPC as severe flare with a moderate
flare reported by the BILAG assessors, but the criteria for
severe flare were present. In 3 of 4 of these cases scored
at a lower level by the BILAG assessors, neurologic items
were underscored as B instead of A for reasons that are
not clear. The patients with severe flares recorded by
BILAG, but moderate flares by TPC, were correctly
scored for BILAG in 9 of 11 cases and were mostly muco-
cutaneous or musculoskeletal flares (8 of 11 cases, with 2
cardiorespiratory flares and 1 renal flare).
DISCUSSION
This paper-patient exercise has allowed the assessment of
a much wider range of clinical problems compared to the
previous live-patient exercise (9). By using over 40
rheumatologists with a major interest in SLE, we were able
to collect a large number of cases for flare assessment and
involved a much larger number of assessors. The disposi-
tion of case review assignments was arranged to ensure
that a similar range of cases was reviewed by all participat-
ing physicians. In the first part of the study, the 988 case
histories were reviewed independently by 3 rheumatolo-
gists, and full agreement as to whether the patient was
experiencing a mild, moderate, or severe flare or experi-
encing persistent/ongoing disease was achieved in 451
cases (46%). Review of discrepant cases suggested that
there were some errors in the scoring of the BILAG 2004
index, without which the levels of agreement would have
been higher, emphasizing the importance of training in
the use of the glossary and the scoring manual. Although
there was some evidence that single-system severe A-level
flares by the BILAG 2004 index in mucocutaneous and
musculoskeletal systems were sometimes perceived to be
moderate-level flares by the TPC, the case descriptions
varied in the amount of detail provided, and attaching
much significance to the small number of cases this
applied to is difficult, given that the presence of a signifi-
cant flare was clear to all assessors.
The case histories with full agreement were then used, in
effect, as our gold standard cases. The 3 lupus flare instru-
ments, i.e., BILAG 2004, SFI, and rSFI, were used to assess
flare in different cases in the second part of the study and
performed equally well, particularly if treatment change
was excluded as a component of the flare score. In practice,
the scores from the pairs of rheumatologists who completed
the BILAG 2004, SFI, or the rSFI demonstrated a high level
of agreement overall with the predetermined TPC level of
flare, and for the specific types of flare, especially for severe
flare (levels of agreement of 85% or higher). Distinguishing
mild and moderate flares from persistent activity/no flare
and severe flare as assessed by the TPC method was more
consistently achieved when the SFI and rSFI instruments
were used without the rules that required all treatment
change to determine flare. This issue has previously been
reported in a smaller retrospective real patient cohort study
(14). Apparently, treatment change by itself will quite fre-
quently fail to indicate worsening disease, as adverse
events, or treatment intolerance, may complicate matters.
As a treat-to-target philosophy gains traction in the manage-
ment of SLE, this philosophy increases the likelihood that
treatment change will be widely used to define flare, when
it may simply reflect fine tuning of managing persistent dis-
ease. Nevertheless an intent-to-treat principle remains use-
ful to broadly reflect clinically important levels of disease
activity.
It should be noted that 7 cases were not scored but were
included in the analysis despite insufficient information,
predominately those for BILAG flare assessment (6 of 7
cases), as this assessment is more demanding in terms of the
information required for accurate and comprehensive com-
pletion of case report forms. Where there was initial discord
in flare scoring for the other cases reported, the pairs
reported that by discussion (usually via telephone confer-
ence) agreement could be reached relatively easily in the
vast majority of cases, even though the quality of the case
scenarios was rather variable. The pairs of assessors only
used 1 instrument, and each of the 3 of types of flare instru-
ments was not used on the same cases by the same people.
In 535 of the 988 cases (54%) originally submitted for
flare assessment, consensus on the level of flare without
using a flare instrument could not be agreed by 3 physi-
cians. Although in some cases there was insufficient infor-
mation for some of the physicians to rate the case, for
example because the severity was not clear enough or the
time of onset of the deterioration was not adequately
defined (to distinguish flare from persistent activity or dam-
age), there were other cases where consensus agreement
could not be achieved despite reasonable scenarios. These
were mostly those cases with multiple systems involved,
presumably because different physicians ranked the com-
ponents differently, particularly if some systems changed
severity to different extents or changed inconsistently, with
some symptoms worse and others stable or improved. This
variability is reminiscent of a problem noted previously
in a study evaluating responsiveness using BILAG and
SLEDAI compared with a physician visual analog scale (15)
and emphasizes the advantage in obtaining consistency of
scoring in flare instruments, with defined glossaries rather
than relying solely on physician opinion. However, limita-
tions of disease definitions that rely on predefined thresh-
olds of severity cannot be excluded.
Although the capacity of paper-patient exercises greatly
increases the range of possible combinations of lupus clini-
cal features for assessment in studies of this kind, nothing
captures the dilemma of lupus assessment as much as a real
patient in front of a clinician. Nevertheless the practicali-
ties of getting large numbers of patients who are actually
flaring into a clinical assessment study of the type that we
reported previously (9) are considerable. In retrospect, we
would probably have obtained greater agreement among
the raters/assessors and a larger panel of cases for flare
assessment with much tighter requirements/standardiza-
tion for the writing of the case histories. An advantage of
the case histories is that they were devised from real clinic
patients. We are aware that there may have been biases in
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that some of the assessors may have been more or less expe-
rienced in the assessment instruments used.
It is not just in SLE that challenges are evident in attempt-
ing to capture flare adequately and distinguish it from ongo-
ing disease. The Outcome Measures in Rheumatology
Rheumatoid Arthritis Flare Group has been involved in
similar studies for several years (16). Their work is ongoing
and the fact that they are dealing with a single organ/system
highlights the added complexity when dealing with lupus.
Although we cannot say that the problem of capturing
flare accurately in patients with lupus is ended, the rela-
tively high levels of agreement obtained with the flare
instruments and weighted kappa coefficients, ranging from
0.59 (SFI instrument with treatment) to 0.82 (for rSFI with-
out treatment and BILAG 2004), was encouraging, espe-
cially given some problems with inadequate histories and
the great diversity of rheumatologists from many countries
involved in the study. All of the instruments used in this
study have construct and content validity based on their
use with these paper-patient scenarios. The choice of
instrument to be used in future flare studies will depend on
the types of patients to be assessed, the need to distinguish
different types of flares, and the training and experience of
the likely investigators.
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